The Use of Release-Active Antibody-Based Preparations for Vertigo Prevention in Adults
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605536929 | ||
| 003 | CHVBK | ||
| 005 | 20210128100854.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20151101xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10517-015-3098-z |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10517-015-3098-z | ||
| 245 | 0 | 4 | |a The Use of Release-Active Antibody-Based Preparations for Vertigo Prevention in Adults |h [Elektronische Daten] |c [V. Barchukov, E. Zhavbert, Yu. Dugina, O. Epstein] |
| 520 | 3 | |a The effectiveness of antibody-based release-active preparations Impaza (antibodies to eNOS), Tenoten (antibodies to brain-specific protein S-100), Dietressa (antibodies to type 1 cannabinoid receptor), Brizantin (combined preparation, antibodies to brain-specific protein S-100 and type 1 cannabinoid receptor), and Divaza (combined preparation, antibodies to brain-specific protein S-100 and eNOS) in the prevention of vertigo was studied on the model of intermittent accumulation of Coriolis accelerations (ICCA). Modification of activity of vestibular receptors and signal systems by release-active preparations contributed to an increase in ICCA tolerance time. Combined preparation Impaza possessed the most significant antinaupathic properties. Brizantin was less potent in this respect. | |
| 540 | |a Springer Science+Business Media New York, 2015 | ||
| 690 | 7 | |a vertigo |2 nationallicence | |
| 690 | 7 | |a release-active antibody-based preparations |2 nationallicence | |
| 690 | 7 | |a Divaza |2 nationallicence | |
| 690 | 7 | |a Brizantin |2 nationallicence | |
| 700 | 1 | |a Barchukov |D V. |u Materia Medica Holding, Moscow, Russia |4 aut | |
| 700 | 1 | |a Zhavbert |D E. |u Materia Medica Holding, Moscow, Russia |4 aut | |
| 700 | 1 | |a Dugina |D Yu |u Materia Medica Holding, Moscow, Russia |4 aut | |
| 700 | 1 | |a Epstein |D O. |u Materia Medica Holding, Moscow, Russia |4 aut | |
| 773 | 0 | |t Bulletin of Experimental Biology and Medicine |d Springer US; http://www.springer-ny.com |g 160/1(2015-11-01), 61-63 |x 0007-4888 |q 160:1<61 |1 2015 |2 160 |o 10517 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10517-015-3098-z |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10517-015-3098-z |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Barchukov |D V. |u Materia Medica Holding, Moscow, Russia |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Zhavbert |D E. |u Materia Medica Holding, Moscow, Russia |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Dugina |D Yu |u Materia Medica Holding, Moscow, Russia |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Epstein |D O. |u Materia Medica Holding, Moscow, Russia |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Bulletin of Experimental Biology and Medicine |d Springer US; http://www.springer-ny.com |g 160/1(2015-11-01), 61-63 |x 0007-4888 |q 160:1<61 |1 2015 |2 160 |o 10517 | ||